Literature DB >> 30476132

Anti-OspA DNA-Encoded Monoclonal Antibody Prevents Transmission of Spirochetes in Tick Challenge Providing Sterilizing Immunity in Mice.

Yang Wang1, Rianne Esquivel2, Seleeke Flingai2, Zachary A Schiller1, Aurélie Kern3, Sangya Agarwal2, Jacqueline Chu2, Ami Patel2, Katherine Sullivan1, Megan C Wise4, Kate E Broderick4, Linden Hu3, David B Weiner2, Mark S Klempner1.   

Abstract

We recently developed anti-OspA human immunoglobulin G1 monoclonal antibodies (HuMAbs) that are effective in preventing Borrelia transmission from ticks in a murine model. Here, we investigated a novel approach of DNA-mediated gene transfer of HuMAbs that provide protection against Lyme disease. Plasmid DNA-encoded anti-OspA HuMAbs inoculated in mice achieved a serum antibody concentration of >6 μg/mL. Among mice injected with DNA-encoded monoclonal antibodies, 75%-77% were protected against an acute challenge by Borrelia-infected ticks. Our results represent the first demonstration of employing DNA transfer as a delivery system for antibodies that block transmission of Borrelia in animal models.
© The Author(s) 2018. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  DMAb; Lyme disease; OspA; human monoclonal antibody

Mesh：

Substances：

Year:  2019        PMID： 30476132      PMCID： PMC6420172          DOI： 10.1093/infdis/jiy627

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


  14 in total

1.  Skin Transfection Patterns and Expression Kinetics of Electroporation-Enhanced Plasmid Delivery Using the CELLECTRA-3P, a Portable Next-Generation Dermal Electroporation Device.

Authors:  Dinah H Amante; Trevor R F Smith; Janess M Mendoza; Katherine Schultheis; Jay R McCoy; Amir S Khan; Niranjan Y Sardesai; Kate E Broderick
Journal:  Hum Gene Ther Methods       Date:  2015-08       Impact factor: 2.396

2.  A vaccine consisting of recombinant Borrelia burgdorferi outer-surface protein A to prevent Lyme disease. Recombinant Outer-Surface Protein A Lyme Disease Vaccine Study Consortium.

Authors:  L H Sigal; J M Zahradnik; P Lavin; S J Patella; G Bryant; R Haselby; E Hilton; M Kunkel; D Adler-Klein; T Doherty; J Evans; P J Molloy; A L Seidner; J R Sabetta; H J Simon; M S Klempner; J Mays; D Marks; S E Malawista
Journal:  N Engl J Med       Date:  1998-07-23       Impact factor: 91.245

3.  Temporal changes in outer surface proteins A and C of the lyme disease-associated spirochete, Borrelia burgdorferi, during the chain of infection in ticks and mice.

Authors:  T G Schwan; J Piesman
Journal:  J Clin Microbiol       Date:  2000-01       Impact factor: 5.948

4.  Lyme disease.

Authors:  Eugene D Shapiro
Journal:  N Engl J Med       Date:  2014-08-14       Impact factor: 91.245

5.  Adverse event reports following vaccination for Lyme disease: December 1998-July 2000.

Authors:  Sarah L Lathrop; Robert Ball; Penina Haber; Gina T Mootrey; M Miles Braun; Sean V Shadomy; Susan S Ellenberg; Robert T Chen; Edward B Hayes
Journal:  Vaccine       Date:  2002-02-22       Impact factor: 3.641

6.  Monoclonal antibodies specific for the outer surface protein A (OspA) of Borrelia burgdorferi prevent Lyme borreliosis in severe combined immunodeficiency (scid) mice.

Authors:  U E Schaible; M D Kramer; K Eichmann; M Modolell; C Museteanu; M M Simon
Journal:  Proc Natl Acad Sci U S A       Date:  1990-05       Impact factor: 11.205

7.  DMAb inoculation of synthetic cross reactive antibodies protects against lethal influenza A and B infections.

Authors:  Sarah T C Elliott; Nicole L Kallewaard; Ebony Benjamin; Leslie Wachter-Rosati; Josephine M McAuliffe; Ami Patel; Trevor R F Smith; Katherine Schultheis; Daniel H Park; Seleeke Flingai; Megan C Wise; Janess Mendoza; Stephanie Ramos; Kate E Broderick; Jian Yan; Laurent M Humeau; Niranjan Y Sardesai; Kar Muthumani; Qing Zhu; David B Weiner
Journal:  NPJ Vaccines       Date:  2017-07-06       Impact factor: 7.344

8.  An engineered bispecific DNA-encoded IgG antibody protects against Pseudomonas aeruginosa in a pneumonia challenge model.

Authors:  Ami Patel; Antonio DiGiandomenico; Ashley E Keller; Trevor R F Smith; Daniel H Park; Stephanie Ramos; Katherine Schultheis; Sarah T C Elliott; Janess Mendoza; Kate E Broderick; Megan C Wise; Jian Yan; Jingjing Jiang; Seleeke Flingai; Amir S Khan; Kar Muthumani; Laurent Humeau; Lily I Cheng; Leslie Wachter-Rosati; C Kendall Stover; Niranjan Y Sardesai; David B Weiner
Journal:  Nat Commun       Date:  2017-09-21       Impact factor: 14.919

9.  Protection against dengue disease by synthetic nucleic acid antibody prophylaxis/immunotherapy.

Authors:  Seleeke Flingai; Emily M Plummer; Ami Patel; Sujan Shresta; Janess M Mendoza; Kate E Broderick; Niranjan Y Sardesai; Kar Muthumani; David B Weiner
Journal:  Sci Rep       Date:  2015-07-29       Impact factor: 4.379

10.  Rapid and Long-Term Immunity Elicited by DNA-Encoded Antibody Prophylaxis and DNA Vaccination Against Chikungunya Virus.

Authors:  Karuppiah Muthumani; Peter Block; Seleeke Flingai; Nagarajan Muruganantham; Itta Krishna Chaaithanya; Colleen Tingey; Megan Wise; Emma L Reuschel; Christopher Chung; Abirami Muthumani; Gopalsamy Sarangan; Padma Srikanth; Amir S Khan; Paluru Vijayachari; Niranjan Y Sardesai; J Joseph Kim; Kenneth E Ugen; David B Weiner
Journal:  J Infect Dis       Date:  2016-03-21       Impact factor: 5.226
View more
  7 in total

Review 1.  Bacterial Amyloids: The Link between Bacterial Infections and Autoimmunity.

Authors:  Lauren Nicastro; Çagla Tükel
Journal:  Trends Microbiol       Date:  2019-08-15       Impact factor: 17.079

Review 2.  DNA vaccines: prime time is now.

Authors:  Ebony N Gary; David B Weiner
Journal:  Curr Opin Immunol       Date:  2020-04-04       Impact factor: 7.486

Review 3.  The year that shaped the outcome of the OspA vaccine for human Lyme disease.

Authors:  Raymond J Dattwyler; Maria Gomes-Solecki
Journal:  NPJ Vaccines       Date:  2022-01-27       Impact factor: 9.399

Review 4.  In Vivo Delivery of Nucleic Acid-Encoded Monoclonal Antibodies.

Authors:  Ami Patel; Mamadou A Bah; David B Weiner
Journal:  BioDrugs       Date:  2020-06       Impact factor: 5.807

5.  Protection against Borreliella burgdorferi infection mediated by a synthetically engineered DNA vaccine.

Authors:  Ghiabe H Guibinga; Bikash Sahay; Heather Brown; Neil Cooch; Jing Chen; Jian Yan; Charles Reed; Meerambika Mishra; Bryan Yung; Holly Pugh; Katherine Schultheis; Rianne N Esquivel; David B Weiner; Laurent H Humeau; Kate E Broderick; Trevor R F Smith
Journal:  Hum Vaccin Immunother       Date:  2020-08-12       Impact factor: 3.452

6.  Active immunoprophylaxis with a synthetic DNA-encoded monoclonal anti-respiratory syncytial virus scFv-Fc fusion protein confers protection against infection and durable activity.

Authors:  Katherine Schultheis; Holly M Pugh; Janet Oh; Jacklyn Nguyen; Bryan Yung; Charles Reed; Neil Cooch; Jing Chen; Jian Yan; Kar Muthumani; Laurent M Humeau; David B Weiner; Kate E Broderick; Trevor R F Smith
Journal:  Hum Vaccin Immunother       Date:  2020-06-16       Impact factor: 3.452

7.  Synthetic DNA Delivery of an Optimized and Engineered Monoclonal Antibody Provides Rapid and Prolonged Protection against Experimental Gonococcal Infection.

Authors:  Elizabeth M Parzych; Sunita Gulati; Bo Zheng; Mamadou A Bah; Sarah T C Elliott; Jacqueline D Chu; Nancy Nowak; George W Reed; Frank J Beurskens; Janine Schuurman; Peter A Rice; David B Weiner; Sanjay Ram
Journal:  mBio       Date:  2021-03-16       Impact factor: 7.867
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.